Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jul;37(7):1504–1505. doi: 10.1128/aac.37.7.1504

Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.

H W Murray 1, J Hariprashad 1, R E Fichtl 1
PMCID: PMC188002  PMID: 8363382

Abstract

In experimental visceral leishmaniasis, euthymic but not athymic (nude) BALB/c mice respond to conventional treatment with pentavalent antimony, indicating that the in vivo efficacy of antimony is T cell dependent. This finding correlates with frequent antimony treatment failures for T-cell-deficient patients with visceral leishmaniasis. To determine whether the in vivo efficacies of alternative antileishmanial agents also require T cells, Leishmania donovani-infected euthymic and nude BALB/c mice were treated with pentamidine or amphotericin B. Pentamidine induced leishmanistatic activity in euthymic mice but had little effect in nude mice. In contrast, amphotericin B exerted potent leishmanicidal activities in both euthymic and nude animals. These results suggest that amphotericin B may be of particular use for T-cell-deficient patients with visceral leishmaniasis.

Full text

PDF
1504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altés J., Salas A., Riera M., Udina M., Galmés A., Balanzat J., Ballesteros A., Buades J., Salvá F., Villalonga C. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS. 1991 Feb;5(2):201–207. [PubMed] [Google Scholar]
  2. Berman J. D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis. 1988 May-Jun;10(3):560–586. doi: 10.1093/clinids/10.3.560. [DOI] [PubMed] [Google Scholar]
  3. Berman J. D., Ksionski G., Chapman W. L., Waits V. B., Hanson W. L. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother. 1992 Sep;36(9):1978–1980. doi: 10.1128/aac.36.9.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berman J. D., Wyler D. J. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis. 1980 Jul;142(1):83–86. doi: 10.1093/infdis/142.1.83. [DOI] [PubMed] [Google Scholar]
  5. Croft S. L., Davidson R. N., Thornton E. A. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):111–118. doi: 10.1093/jac/28.suppl_b.111. [DOI] [PubMed] [Google Scholar]
  6. Davidson R. N., Croft S. L., Scott A., Maini M., Moody A. H., Bryceson A. D. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet. 1991 May 4;337(8749):1061–1062. doi: 10.1016/0140-6736(91)91708-3. [DOI] [PubMed] [Google Scholar]
  7. Fernández-Guerrero M. L., Aguado J. M., Buzón L., Barros C., Montalbán C., Martín T., Bouza E. Visceral leishmaniasis in immunocompromised hosts. Am J Med. 1987 Dec;83(6):1098–1102. doi: 10.1016/0002-9343(87)90948-x. [DOI] [PubMed] [Google Scholar]
  8. Mishra M., Biswas U. K., Jha D. N., Khan A. B. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992 Nov 21;340(8830):1256–1257. doi: 10.1016/0140-6736(92)92952-c. [DOI] [PubMed] [Google Scholar]
  9. Murray H. W., Berman J. D., Wright S. D. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis. 1988 May;157(5):973–978. doi: 10.1093/infdis/157.5.973. [DOI] [PubMed] [Google Scholar]
  10. Murray H. W., Oca M. J., Granger A. M., Schreiber R. D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest. 1989 Apr;83(4):1253–1257. doi: 10.1172/JCI114009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Thakur C. P., Kumar M., Kumar P., Mishra B. N., Pandey A. K. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) 1988 Jun 4;296(6636):1557–1561. doi: 10.1136/bmj.296.6636.1557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Thakur C. P., Kumar M., Pandey A. K. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg. 1991 Oct;45(4):435–441. doi: 10.4269/ajtmh.1991.45.435. [DOI] [PubMed] [Google Scholar]
  13. Trotter E. R., Peters W., Robinson B. L. The experimental chemotherapy of leishmaniasis, IV. The development of a rodent model for visceral infection. Ann Trop Med Parasitol. 1980 Apr;74(2):127–138. doi: 10.1080/00034983.1980.11687322. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES